Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …

More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths
occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit …

Background The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic
agents has shown promising efficacy in unresectable hepatocellular carcinoma (HCC), but …

Background: Hepatocellular carcinoma (HCC) persists as a dominant cause of cancer-
related mortality globally, with a notably rapid escalation in mortality rates. The advent of …

Introduction Patients with advanced hepatocellular carcinoma have a dismal prognosis; only
a subset of patients with advanced HCC will benefit from treatment with immunotherapy. We …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Background Immunotherapy based on immune checkpoint inhibitors (ICIs) has become the
first-line treatment for unresectable hepatocellular carcinoma (uHCC). However, only a small …

Biomarkers for predicting the treatment efficacy of immune checkpoint inhibitor (ICI)-based
therapy in patients with unresectable hepatocellular carcinoma (uHCC) are crucial. Previous …

Background Immune checkpoint inhibitors (ICI) are increasingly used in hepatocellular
carcinoma (HCC) trials. However, the correlations between early endpoints, such as …

Background & Aims We investigated the efficacy and safety of immune checkpoint inhibitor
(ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based …